over 30 years of experience in training and providing further education in technical and interdisciplinary fields. It trains over 3,000 participants annually. The centre offers a wide range of basic and advanced training courses for both professionals and others working with ionising radiation or radioactive materials. The courses, in which participants acquire the relevant expertise, are recognised by the Federal Office of Public Health (FOPH) and the Swiss Federal Nuclear Safety Inspectorate (ENSI). It also runs basic and advanced training courses for PSI's staff and interested individuals from the ETH Domain. Since 2015, courses on human resources development (such as conflict management, leadership workshops, communication and transferable skills) have also been held. The quality of the PSI Education Centre is certified (ISO 29990:2001). Cooperation with industry PSI holds about 100 active patent families in, for example, medicine, with investigation techniques for proton therapy against cancer or for the detection of prions, the cause of mad cow disease. Other patent families are in the field of photoscience, with special lithography processes for structuring surfaces, in the environmental sciences for recycling rare earths, for catalysts or for the gasification of biomass, in the materials sciences and in other fields. PSI maintains its own technology transfer office for patents. Patents have, for example, been granted for detectors used in high-performance X-ray cameras developed for the Swiss Synchrotron Light Source SLS, which can be used to investigate materials at the atomic level. These provided the basis for founding the company DECTRIS, the largest spin-off to date to emerge from PSI. In 2017, the Lausanne-based company Debiopharm licensed the active substance 177Lu-PSIG-2, which was developed at the Centre for Radiopharmaceutical Sciences at PSI. This substance is effective in treating a type of thyroid cancer. It is to be further developed under the name DEBIO 1124 with the aim to have it approved and get it ready for market launch. Another PSI spin-off, GratXray, works with a method based on phase contrasts in lattice interferometry. The method was originally developed to characterize synchrotron radiation and is expected to become the gold standard in screening for breast cancer. The new technology has already been used in a prototype that PSI developed in collaboration with Philips. See also Science and technology in Switzerland Swiss Innovation Park Proton therapy References External links PSI Homepage Website of SLS Website of SINQ Website of SwissFEL Proton therapy program High-Intensity-Proton-Accelerators at PSI